GlassScriptPhysician profile
Angalene D Jackson
NPI 1770994766
$1,162.03
in general payments reported to CMS, 2019-2025
24 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $87.27 · 2022: $43.23 · 2024: $396 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.17 | 2019-2022 | |
| Shield Therapeutics INC | $154.69 | 2024 | |
| Astellas Pharma US INC | $101.35 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $99.30 | 2019-2025 | |
| Pfizer INC. | $70.58 | 2019-2022 | |
| Lupin INC. | $68.41 | 2019-2020 | |
| Hologic Sales and Service, LLC | $57.42 | 2019-2024 | Novasure |
| Biogen, INC. | $42.36 | 2024 | Vumerity |
| Cumberland Pharmaceuticals, INC. | $41.87 | 2019-2020 | |
| Baxter Healthcare | $40.66 | 2025 | Perclot |
| Duchesnay USA Incorporated | $37.07 | 2019 | |
| Mission Pharmacal Company | $33.65 | 2019 | |
| Organon LLC | $30.90 | 2024-2025 | Nexplanon |
| Roche Diagnostics Corporation | $26.08 | 2019 | |
| Mayne Pharma Commercial LLC | $22.33 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.26 | 2019 | |
| Mimedx Group, INC. | $20.41 | 2024 | |
| Coopersurgical, INC. | $19.34 | 2025 | Paragard T 380a |
| Pacira Pharmaceuticals Incorporated | $18.59 | 2025 | Exparel |
| Agile Therapeutics, INC. | $15.08 | 2024 | Twirla |
| Mylan Pharmaceuticals INC. | $13.69 | 2019 | |
| Exeltis, USA INC. | $13.55 | 2024 | Slynd |
| Therapeuticsmd, INC. | $13.18 | 2020 | |
| Allergan, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angalene Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.